Furthermore, 80% of NSCLC-KRAS mutations involve a glycine on position 12 substitution (KRASG12C, KRASG12V, KRASG12D...) and 11% involve a glycine on position 13 substitution (KRASG13C, KRASG13D, KRASG13R...). Here, KRAS is linked to non-small cell lung carcinoma.